MPM Bioimpact LLC lowered its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 1.5% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 8,442,783 shares of the company's stock after selling 125,113 shares during the period. Compass Therapeutics comprises about 2.8% of MPM Bioimpact LLC's portfolio, making the stock its 14th largest holding. MPM Bioimpact LLC owned 6.11% of Compass Therapeutics worth $16,041,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently modified their holdings of CMPX. Tower Research Capital LLC TRC increased its stake in shares of Compass Therapeutics by 298.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after purchasing an additional 12,917 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Compass Therapeutics in the 4th quarter valued at about $27,000. Mariner LLC purchased a new position in shares of Compass Therapeutics in the 4th quarter valued at about $30,000. Squarepoint Ops LLC purchased a new position in shares of Compass Therapeutics in the 4th quarter valued at about $35,000. Finally, ProShare Advisors LLC increased its stake in shares of Compass Therapeutics by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock valued at $42,000 after purchasing an additional 9,451 shares in the last quarter. Hedge funds and other institutional investors own 68.43% of the company's stock.
Analyst Ratings Changes
Several equities analysts recently weighed in on the company. D. Boral Capital restated a "buy" rating and issued a $32.00 price target on shares of Compass Therapeutics in a research note on Tuesday, August 12th. Raymond James Financial upgraded Compass Therapeutics to an "outperform" rating and set a $9.00 price objective on the stock in a report on Tuesday, July 1st. Finally, Guggenheim lifted their price objective on Compass Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating and nine have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $12.89.
Get Our Latest Report on CMPX
Compass Therapeutics Price Performance
Shares of Compass Therapeutics stock opened at $3.49 on Tuesday. The stock has a market cap of $482.60 million, a P/E ratio of -7.76 and a beta of 1.50. The stock's 50 day simple moving average is $2.95 and its 200-day simple moving average is $2.47. Compass Therapeutics, Inc. has a 1-year low of $1.25 and a 1-year high of $4.08.
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). As a group, research analysts expect that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.
About Compass Therapeutics
(
Free Report)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
Further Reading
Want to see what other hedge funds are holding CMPX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Compass Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.
While Compass Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
